Keyphrases
Phase II Study
100%
Brain Metastases
100%
Whole Brain Radiation Therapy
100%
Control Arm
75%
Median Survival Time
50%
Response Rate
50%
Breast Cancer
50%
Hazard Ratio
50%
Non-small Cell Lung Cancer (NSCLC)
50%
Breast Cancer Patients
50%
Supplemental Oxygen
50%
Regression Analysis
25%
Severe Adverse Events
25%
Partial Response
25%
Further Analysis
25%
Complete Response
25%
Metastasis
25%
Hemoglobin
25%
Solid Tumors
25%
Risk of Death
25%
Hypoxemia
25%
Confirmatory Trials
25%
Karnofsky Performance Status
25%
Patients with Breast Cancer
25%
Non-cytotoxic
25%
Allosteric Modifiers
25%
Radiation Sensitizer
25%
P-16
25%
Medicine and Dentistry
Brain Metastasis
100%
Whole Brain Radiotherapy
100%
Efaproxiral
100%
Breast Cancer
50%
Arm
30%
Median Survival Time
20%
Hazard Ratio
20%
Non Small Cell Lung Cancer
20%
Metastatic Carcinoma
10%
Solid Malignant Neoplasm
10%
Hypoxemia
10%
Adverse Event
10%
Karnofsky Performance Status
10%
Radiosensitizer
10%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Metastasis
100%
Efaproxiral
100%
Breast Cancer
50%
Non Small Cell Lung Cancer
20%
Median Survival Time
20%
Adverse Event
10%
Solid Malignant Neoplasm
10%
Hypoxemia
10%
Radiosensitizing Agent
10%
Immunology and Microbiology
Arm
100%
Median Survival Time
66%
Sensitization
33%
Nursing and Health Professions
Efaproxiral
100%
Radiosensitizing Agent
10%